02.12.2021 • News

Azelis Acquires Austria’s Neupert Specialities

Azelis has acquired Neupert Specialities, an Austrian distributor specializing in food and health raw materials and ingredients in its local market, as well as in Germany and Switzerland. The deal strengthens the Belgium-based distributor’s presence in the growing Austrian food and health segment and in the region’s broader life sciences market, also adding cross-selling opportunities.

Financial details of the transaction were not disclosed.

“There is an outstanding compatibility between our two companies and we are very excited about the enhanced opportunity to expand the business under Azelis’ ownership by leveraging combined global principal relationships. Azelis’ strong track record in sustainability, especially their EcoVadis Platinum rating, as well as the technological capabilities, are of particularly great value to our joint food and health customer base,” said Peter Suppan, Neupert’s founder and managing director.

Headquartered in Vienna, Neupert specializes in products such as proteins, hydrocolloids, agar and sugar substitutes. The company was founded by Suppan and Norbert Resch, both of whom will continue to lead the business.

In late October, Azelis also agreed to acquire 90% of the shares in South Africa’s Umongo, a leading distributor of lubricants and metal working fluids. The transaction is expected to close by the end of this year. Umongo has its head office in Durban and employs 35 people. It also has an application laboratory. CEO Boston Moonsamy will remain with the company and continue to lead the business.

Author: Elaine Burridge, Freelance Journalist

(c) Azelis
(c) Azelis

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read